Skip to main content
. 2004 Feb;6(1):42–51. doi: 10.1016/S1525-1578(10)60490-4

Table 2.

Comparison of IHC, FISH, and Real-Time PCR Analyses of HER-2 in Formalin-Fixed, Paraffin-Embedded Breast Tumors

Group* Case no. Hercep1&2 0, 1+, 2+, 3+ FISH HER-2/CEP 17 Ratio mRNA§ HER-2/ β-actin N = 5 Ratio DNA HER-2/gastrin N = 5
A 1 3 >7.0 149.88 [107.55; 179.38] 23.22 [10.58; 30.48]
2 3 6.0 85.50 [23.01; 130.19] 19.59 [6.6; 34.25]
3 3 3.1 No result 2.33 [0.62; 34.44]
4 3 >7.5 182.92 [105.93; 262.1] 67.45 [41.22; 77.66]
5 3 6.0 222.12 [183.96; 262.1] 43.79 [7.3; 94.38]
6 3 6.6 24.46 [3.52; 43.97] 17.98 [6.67; 25.63]
7 3 4.2 29.59 [10.53; 43.67] 4.12 [1.98; 6.48]
8 3 4.0 65.86 [33.78; 120.2] 7.48 [4.73; 11.18]
B 9 2 1.1 17.06 [9.71; 35.88] 2.89 [1.8; 3.42]
10 2 1.1 4.82 [3.35; 7.98] 2.46 [1.51; 2.69]
11 2 1.1 58.93 [31.39; 98.55] 2.08 [1.85; 2.38]
12 2 1.2 6.59 [5.42; 10.05] 1.88 [1.38; 2.15]
13 2 0.9 61.61 [42.65; 82.67] 2.13 [1.44; 2.57]
14 2 1.0 7.67 [4.52; 11.29] 1.91 [0.86; 3.01]
15 2 1.0 4.82 [0.92; 9.69] 2.6 [1.87; 3.93]
16 2 1.0 2.85 [1.93; 5.1] 1.98 [1.24; 2.4]
C 17 1 0.8 18.05 [8.54; 36.41] 0.93 [0.67; 1.14]
18 1 1.1 43.85 [34.81; 51.71] 0.64 [0.03; 1.24]
19 1 1.1 8.62 [3.46; 19.41] 0.34 [0.09; 0.93]
20 1 0.9 26.23 [10.74; 63.1] 0.37 [0.05; 0.73]
21 1 1.1 17.45 [10.64; 35.95] 1.58 [1.26; 1.74]
22 1 1.1 9.89 [6.38; 13.27] 1.45 [0.16; 2.57]
23 1 1.3 13.93 [9.55; 21.75] 1.12 [0.28; 1.58]
24 1 0.9 10.61 [6.1; 13.89] 1.24 [0.54; 3.15]
D 25 0 1.0 51.53 [7.77; 130.58] 1.79 [0.86; 2.46]
26 0 1.0 0.46 [0.32; 0.76] 1.98 [1.19; 2.52]
27 0 1.0 35.51 [4.25; 104.4] 1.53 [0.86; 1.9]
E 28 1 1.1 33.33 [13.99; 41.3] 0.96 [0.34; 1.47]
29 1 2.4 7.15 [2.95; 10.58] 2.15 [1.99; 2.33]
30 1 1.4 29.92 [7.18; 95.76] 1.86 [0.93; 2.71]
*

Groups A–D = Invasive ductal carcinomas (HercepTest 3+, 2+, 1+ positive; 0, negative). Group E = DCIS. 

Duplicate blinded HER-2 protein expression assay (HercepTest). 

CEP 17 = probe for chromosome 17 centromere region. 

§

Relative HER-2/neu mRNA expression (Her-2/neu/β-actin) in absolute values. Values are given as means, with min and max values. 

Relative HER-2/neu gene amplification in accordance with the LightCycler HER2/neu DNA Quantification kit (Roche). Values are given as means, with min and max values. 

Insufficient mRNA for analyzing both HER-2 and β-actin. 

A–D = Invasive ductal carcinomas. 

E = DCIS cases. 

Abbreviations: DCIS, ductal carcinoma in situ; IHC, immunohistochemistry; FFPE, formalin-fixed, paraffin-embedded; FISH, fluorescence in situ hybridization.